Ali Jalali1, Erin Rothwell2, Jeffrey R Botkin3, Rebecca A Anderson3, Russell J Butterfield4, Richard E Nelson5. 1. Department of Population Health Sciences, Weill Cornell Medical College, New York, NY. Electronic address: alj4004@med.cornell.edu. 2. Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, UT. 3. Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT; Utah Center of Excellence in ELSI Research, Salt Lake City, UT. 4. Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT. 5. Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT; IDEAS Center, Veterans Administration Salt Lake City Health Care System, Salt Lake City, UT.
Abstract
OBJECTIVE: To evaluate the cost-effectiveness of nusinersen with and without universal newborn screening for infantile-onset spinal muscular atrophy (SMA). STUDY DESIGN: A Markov model using data from clinical trials with US epidemiologic and cost data was developed. The primary interventions studied were nusinersen treatment in a screening setting, nusinersen treatment in a nonscreening setting, and standard care. Analysis was conducted from a societal perspective. RESULTS: Compared with no screening and no treatment, the incremental cost-effectiveness ratio (ICER) for nusinersen with screening was $330 558 per event-free life year (LY) saved, whereas the ICER for nusinersen treatment without screening was $508 481 per event-free LY saved. For nusinersen with screening to be cost-effective at a willingness-to-pay (WTP) threshold of $50 000 per event-free LY saved, the price would need to be $23 361 per dose, less than one-fifth its current price of $125 000. Preliminary data from the NURTURE trial indicated an 85.7% improvement in expected LYs saved compared with our base results. In probabilistic sensitivity analysis, nusinersen and screening was a preferred strategy 93% of the time at a $500 000 WTP threshold. CONCLUSION: Universal newborn screening for SMA provides improved economic value for payers and patients when nusinersen is available.
OBJECTIVE: To evaluate the cost-effectiveness of nusinersen with and without universal newborn screening for infantile-onset spinal muscular atrophy (SMA). STUDY DESIGN: A Markov model using data from clinical trials with US epidemiologic and cost data was developed. The primary interventions studied were nusinersen treatment in a screening setting, nusinersen treatment in a nonscreening setting, and standard care. Analysis was conducted from a societal perspective. RESULTS: Compared with no screening and no treatment, the incremental cost-effectiveness ratio (ICER) for nusinersen with screening was $330 558 per event-free life year (LY) saved, whereas the ICER for nusinersen treatment without screening was $508 481 per event-free LY saved. For nusinersen with screening to be cost-effective at a willingness-to-pay (WTP) threshold of $50 000 per event-free LY saved, the price would need to be $23 361 per dose, less than one-fifth its current price of $125 000. Preliminary data from the NURTURE trial indicated an 85.7% improvement in expected LYs saved compared with our base results. In probabilistic sensitivity analysis, nusinersen and screening was a preferred strategy 93% of the time at a $500 000 WTP threshold. CONCLUSION: Universal newborn screening for SMA provides improved economic value for payers and patients when nusinersen is available.
Authors: Richard S Finkel; Eugenio Mercuri; Basil T Darras; Anne M Connolly; Nancy L Kuntz; Janbernd Kirschner; Claudia A Chiriboga; Kayoko Saito; Laurent Servais; Eduardo Tizzano; Haluk Topaloglu; Már Tulinius; Jacqueline Montes; Allan M Glanzman; Kathie Bishop; Z John Zhong; Sarah Gheuens; C Frank Bennett; Eugene Schneider; Wildon Farwell; Darryl C De Vivo Journal: N Engl J Med Date: 2017-11-02 Impact factor: 91.245
Authors: Samiah Al-Zaidy; A Simon Pickard; Kavitha Kotha; Lindsay N Alfano; Linda Lowes; Grace Paul; Kathleen Church; Kelly Lehman; Douglas M Sproule; Omar Dabbous; Benit Maru; Katherine Berry; W David Arnold; John T Kissel; Jerry R Mendell; Richard Shell Journal: Pediatr Pulmonol Date: 2018-12-12
Authors: Hanns Lochmüller; David Evans; Wildon Farwell; Richard Finkel; Nathalie Goemans; Mencia de Lemus; Vitaliy Matyushenko; Francesco Muntoni; Marie-Christine Ouillade; Inge Schwersenz; Petra Wilson Journal: J Neuromuscul Dis Date: 2018
Authors: Eve Fouarge; Arnaud Monseur; Bruno Boulanger; Mélanie Annoussamy; Andreea M Seferian; Silvana De Lucia; Charlotte Lilien; Leen Thielemans; Khazal Paradis; Belinda S Cowling; Chris Freitag; Bradley P Carlin; Laurent Servais Journal: Orphanet J Rare Dis Date: 2021-01-06 Impact factor: 4.123
Authors: Sophy T F Shih; Elena Keller; Veronica Wiley; Michelle A Farrar; Melanie Wong; Georgina M Chambers Journal: Int J Neonatal Screen Date: 2022-07-20